The only four medications currently approved by the Food and Drug Administration (FDA) for the management of AD are either acetylcholinesterase (AChE) inhibitors [donepezil (DPZ), galantamine, and rivastigmine] or N-methyl-D-aspartate (NMDA) receptor antagonists [memantine]. The gene discussed is ACHE; the disease is Alzheimer disease.